EN9 Stock Overview
Enzymatica AB (publ), a life science company, develops and sells products that treat and alleviate infections and symptoms in the upper respiratory tract.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Enzymatica AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.25 |
| 52 Week High | kr0.34 |
| 52 Week Low | kr0.18 |
| Beta | -0.051 |
| 1 Month Change | -17.76% |
| 3 Month Change | -8.09% |
| 1 Year Change | -1.96% |
| 3 Year Change | -75.25% |
| 5 Year Change | n/a |
| Change since IPO | -85.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| EN9 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 5.5% | 2.7% | 1.1% |
| 1Y | -2.0% | -21.6% | 6.5% |
Return vs Industry: EN9 exceeded the German Pharmaceuticals industry which returned -22.6% over the past year.
Return vs Market: EN9 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| EN9 volatility | |
|---|---|
| EN9 Average Weekly Movement | 9.6% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: EN9 has not had significant price volatility in the past 3 months.
Volatility Over Time: EN9's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 16 | Claus Egstrand | www.enzymatica.se |
Enzymatica AB (publ), a life science company, develops and sells products that treat and alleviate infections and symptoms in the upper respiratory tract. The company’s product includes ColdZyme, a mouth spray to treat and alleviate cold and flu symptoms. It also provides enzyme formulations for skin care.
Enzymatica AB (publ) Fundamentals Summary
| EN9 fundamental statistics | |
|---|---|
| Market cap | €48.19m |
| Earnings (TTM) | -€4.59m |
| Revenue (TTM) | €4.04m |
11.9x
P/S Ratio-10.5x
P/E RatioIs EN9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EN9 income statement (TTM) | |
|---|---|
| Revenue | kr47.29m |
| Cost of Revenue | kr16.91m |
| Gross Profit | kr30.38m |
| Other Expenses | kr84.05m |
| Earnings | -kr53.67m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 18, 2024
| Earnings per share (EPS) | -0.31 |
| Gross Margin | 64.25% |
| Net Profit Margin | -113.50% |
| Debt/Equity Ratio | 33.4% |
How did EN9 perform over the long term?
See historical performance and comparison